Privately-funded Glycotope GmbH of Germany has raised €55 million in additional equity from its investors in order to complete proof-of-concept studies of two antibody therapeutics for cancer that have been developed using glycosylation technology. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
